Akebia Therapeutics Inc
NASDAQ:AKBA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (1.7), the stock would be worth $1.52 (7% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.6 | $1.42 |
0%
|
| 3-Year Average | 1.7 | $1.52 |
+7%
|
| 5-Year Average | 1.7 | $1.5 |
+6%
|
| Industry Average | 6.7 | $5.99 |
+322%
|
| Country Average | 2.4 | $2.17 |
+53%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$350.4m
|
/ |
Jan 2026
$236.2m
|
= |
|
|
$350.4m
|
/ |
Dec 2026
$236.1m
|
= |
|
|
$350.4m
|
/ |
Dec 2027
$196.7m
|
= |
|
|
$350.4m
|
/ |
Dec 2028
$257.4m
|
= |
|
|
$350.4m
|
/ |
Dec 2029
$319m
|
= |
|
|
$350.4m
|
/ |
Dec 2030
$432.5m
|
= |
|
|
$350.4m
|
/ |
Dec 2031
$494.1m
|
= |
|
|
$350.4m
|
/ |
Dec 2032
$546m
|
= |
|
|
$350.4m
|
/ |
Dec 2033
$594.7m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Akebia Therapeutics Inc
NASDAQ:AKBA
|
376.9m USD | 1.6 | -70.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
348.9B USD | 5.7 | 83.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183.4B USD | 5 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.5B USD | 5.4 | 18.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
108.2B USD | 9 | 27.4 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.7B USD | 5.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 11.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
63.6B AUD | 2.7 | 30.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.2 |
| Median | 2.4 |
| 70th Percentile | 4.1 |
| Max | 4 613 274.2 |
Other Multiples
Akebia Therapeutics Inc
Glance View
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.
